Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Effective ways to prevent arthropathy in severe hemophilia are unknown. METHODS: We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses totaling a minimum of 80 IU of factor VIII per kilogram of body weight at the time of a joint hemorrhage. The primary outcome was the incidence of bone or cartilage damage as detected in index joints (ankles, knees, and elbows) by radiography or magnetic resonance imaging (MRI). RESULTS: Sixty-five boys younger than 30 months of age were randomly assigned to prophylaxis (32 boys) or enhanced episodic therapy (33 boys). When the boys reached 6 years of age, 93% of those in the prophylaxis group and 55% of those in the episodic-therapy group were considered to have normal index-joint structure on MRI (P=0.006). The relative risk of MRI-detected joint damage with episodic therapy as compared with prophylaxis was 6.1 (95% confidence interval, 1.5 to 24.4). The mean annual numbers of joint and total hemorrhages were higher at study exit in the episodic-therapy group than in the prophylaxis group (P<0.001 for both comparisons). High titers of inhibitors of factor VIII developed in two boys who received prophylaxis; three boys in the episodic-therapy group had a life-threatening hemorrhage. Hospitalizations and infections associated with central-catheter placement did not differ significantly between the two groups. CONCLUSIONS: Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00207597 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although effective, ERT is limited by an approximately 40% noncompliance rate, costs ≥$200,000 annually, and advances arthropathy.172, 173, 174, 175”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [172]
Citations
Cites
Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B
NILSSON, I. M., BERNTORP, E., LÖFQVIST, T., & PETTERSSON, H. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00546.x · Cited by 961
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
ALEDORT, L. M., HASCHMEYER, R. H., PETTERSSON, H., & THE ORTHOPAEDIC OUTCOME STUDY GROUP (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00815.x · Cited by 611
A Radiologic Classification of Hemophilic Arthropathy
PETTERSSON, H., AHLBERG, Å., & NILSSON, I. M. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198006000-00018 · Cited by 549
Proceedings: A more uniform measurement of factor VIII inhibitors.
Ck, K., Aledort, L. M., Aronson, D. D., Counts, R., Edson, van Eys, J., Fratantoni, J. C., Green, D., Hampton, J., Hilgartner, M. W., et al. (1975) · PubMed · Cited by 346
Barriers to compliance with prophylaxis therapy in haemophilia
Hacker, M. R., Geraghty, S., & Manco-Johnson, M. (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00534.x · Cited by 261
Self-citationAhlberg, Å. (1965) · Acta Orthopaedica Scandinavica · doi:10.3109/ort.1965.36.suppl-77.01 · Cited by 252
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors
Soucie, J. M. (2004) · Blood · doi:10.1182/blood-2003-05-1457 · Cited by 244
Self-citationIorio, A., Marchesini, E., Marcucci, M., Stobart, K., & Chan, A. K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003429.pub4 · Cited by 192
Nuss, R., Kilcoyne, R. F., Geraghty, S., Shroyer, A. L. W., Rosky, J. W., Mawhinney, S., Wiedel, J., & Manco‐Johnson, M. (2000) · Haemophilia · doi:10.1046/j.1365-2516.2000.00383.x · Cited by 159
Self-citationLee, C. A., Kessler, C. M., Varon, D., Martinowitz, U. P., Heim, M., Kreuz, W., Escuriola‐Ettingshausen, C., Funk, M. J., SCHMIDT, H., & Kornhuber, B. (1998) · Haemophilia · doi:10.1046/j.1365-2516.1998.440413.x · Cited by 154
Research works printed but not linked: 5
- Robinson PM, 1967, Can Med Assoc J, 97, 559
- Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis. Medical bulletin #193. New York: National Hemophilia Foundation, March 11, 1994.
- Stobart K, 2006, Cochrane Database Syst Rev, 2, CD003429
- Kasper CK, 1975, Thromb Diath Haemorr, 34, 612
- Report on the Universal Data Collection Program. Atlanta: Centers for Disease Control and Prevention, 2005;7(1):28. (Accessed July 18, 2007, athttp://www.cdc.gov/ncbddd/hbd/documents/UDC7%281%29.pdf.)
Cited by
Items 301–400 of 1,000
Pathophysiological Role of Synovitis in Hemophilic Arthropathy Development: A Two-Hit Hypothesis
Calcaterra, I. L., Iannuzzo, G., Dell’Aquila, F., & Minno, M. N. D. D. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00541 · Cited by 52
The More Recent History of Hemophilia Treatment
Franchini, M., & Mannucci, P. M. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1756188 · Cited by 58
The hope and reality of long‐acting hemophilia products
Pipe, S. W. (2012) · American Journal of Hematology · doi:10.1002/ajh.23146 · Cited by 48
“Regular, long-term prophylactic therapy with factor concentrates prevents recurrent hemarthroses and reduces or prevents the development of hemophilic arthropathy [3,4].”
BackgroundRANK-RANKL-OPG in Hemophilic Arthropathy: From Clinical and Imaging Diagnosis to Histopathology
Melchiorre, D., Milia, A. F., Linari, S., Romano, E., BENELLI, G., Manetti, M., Guiducci, S., CECCARELLI, C., Innocenti, M., Carulli, C., et al. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.120370 · Cited by 56
Baker, J., Riske, B., Drake, J. H., Forsberg, A. D., Atwood, R., Voutsis, M., & Shearer, R. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02915.x · Cited by 53
Self-citationNijdam, A., Foppen, W., de Kleijn, P., Mauser‐Bunschoten, E. P., Roosendaal, G., van Galen, K. P. M., Schutgens, R. E. G., van der Schouw, Y. T., & Fischer, K. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-08-0637 · Cited by 48
“However, low bleeding rates may not guarantee good joint health as subclinical joint bleeding has been reported to cause arthropathy in patients receiving on-demand treatment (15).”
BackgroundInfluentialPlut, D., Kotnik, B. F., Zupan, I. P., Ključevšek, D., Vidmar, G., Snoj, Ž., Martinoli, C., & Salapura, V. (2019) · Radiology and Oncology · doi:10.2478/raon-2019-0027 · Cited by 48
Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein
McCue, J. T., Kshirsagar, R., Selvitelli, K., Lü, Q., Zhang, M., Mei, B., Peters, R., Pierce, G. F., Dumont, J., Raso, S. W., et al. (2015) · Biologicals · doi:10.1016/j.biologicals.2015.05.012 · Cited by 48
“While the use of recombinant FVIII (rFVIII) and improved purification methodology contributed to significant improvements in the availability and safety of FVIII replacement therapy [2], periodic supply shortages and manufacturing quality breaches have continued into the 2000s.”
Roctavian gene therapy for hemophilia A
Samelson‐Jones, B. J., Small, J. C., & George, L. A. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011847 · Cited by 58
“24 Current HA standard-of-care include recurrent intravenous exogenous FVIII infusion 2 to 4 times per week or subcutaneous administration of the FVIII mimetic, emi-cizumab (Hemlibra; Genentech), 1 to 4 times per month 25-27 to prevent bleeding.”
Hemophilic arthropathy in patients with von Willebrand disease
van Galen, K. P. M., Mauser‐Bunschoten, E. P., & Leebeek, F. W. G. (2012) · Blood Reviews · doi:10.1016/j.blre.2012.09.002 · Cited by 47
Systemic sclerosis trial design moving forward
Johnson, S. R., Khanna, D., Allanore, Y., Matucci‐Cerinic, M., & Furst, D. E. (2016) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000198 · Cited by 47
“Recent advances in research methodology can rise to some of these challenges and these novel strategies have been successfully applied in other areas of rheumatology (4, 6-9).”
BackgroundSun, J., Hua, B., Livingston, E. W., Taves, S., Johansen, P. B., Hoffman, M., Ezban, M., Monroe, D. M., Bateman, T. A., & Monahan, P. E. (2017) · Blood · doi:10.1182/blood-2016-08-734053 · Cited by 47
Management of rare coagulation disorders in 2018
Jain, S., & Acharya, S. S. (2018) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2018.10.009 · Cited by 47
Mancuso, M. E., Lubetsky, A., Pan‐Petesch, B., Lissitchkov, T. J., Nagao, A., Seifert, W. F., Li, Y., & Santagostino, E. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14778 · Cited by 47
Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
Gelbenegger, G., Schoergenhofer, C., Knöbl, P., & Jilma, B. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1714279 · Cited by 46
New challenges in hemophilia: long-term outcomes and complications
Young, G. A. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.362.3798344 · Cited by 47
Imaging and staging of haemophilic arthropathy
Jelbert, A., Vaidya, S., & Fotiadis, N. (2009) · Clinical Radiology · doi:10.1016/j.crad.2009.07.005 · Cited by 46
“The number of clinically overt joint bleeds and the detection of joint abnormalities at clinical examination are poorly correlated with the MRI evidence of joint damage, with the presence of abnormalities on MRI before any reported clinical bleeding episode.(10) There has been shown to be a high correlation between th…”
BackgroundIDO1 suppresses inhibitor development in hemophilia A treated with factor VIII
Matino, D., Gargaro, M., Santagostino, E., Di Minno, M. N. D., Castaman, G., Morfini, M., Rocino, A., Mancuso, M. E., Di Minno, G., Coppola, A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81859 · Cited by 46
Groen, W. G., van der Net, J. J., BOS, K., Abad, A., BERGSTROM, B. ‐., Blanchette, V. S., Feldman, B. M., Funk, S. M., Helders, P. J. M., Hilliard, P., et al. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02606.x · Cited by 46
Self-citationReal‐life experience in switching to new extended half‐life products at European haemophilia centres
Peyvandi, F., Garagiola, I., Boscarino, M., Ryan, A., Hermans, C. R. J. R., & Makris, M. (2019) · Haemophilia · doi:10.1111/hae.13834 · Cited by 53
Pasi, J., Fischer, K., Ragni, M. V., Kulkarni, R., Ozelo, M. C., Mahlangu, J. N., Shapiro, A. D., P’ng, S., Chambost, H., Nolan, B., et al. (2020) · Haemophilia · doi:10.1111/hae.14036 · Cited by 46
“Median (range) age, years 29 (13-62) 34 (13-63) 33 (19-63) 25 (20-62) 3 (3-5) 9 (7-10) 11 (9-12)”
Self-citationUpdate on the Clot Waveform Analysis
Wada, H., Matsumoto, T., Ohishi, K., Shiraki, K., & Shimaoka, M. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620912027 · Cited by 46
“Prophylactic treatment with FVIII concentrate is preferred to prevent bleeding and joint damages in children with severe hemophilia.(26,27) Extending the half-life FVIII (EHL-FVIII) would substantially improve treatment options for patients with hemophilia A.”
BackgroundBerntorp, E. E., Archey, W., Auerswald, G., Federici, A. B., Franchini, M., Knaub, S., Kreuz, W., Lethagen, S., Mannucci, P. M., Pöllmann, H., et al. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01049.x · Cited by 46
“There is evidence suggesting that long-term prophylaxis should be started soon after a child’s first joint bleed (in most cases before the age of 2 yr) so as to avoid arthropathy in adulthood (74, 75).”
BackgroundValentino, L. A., Hakobyan, N., & Enockson, C. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.03.017 · Cited by 46
Self-citationEmerging and future therapies for hemophilia
Carr, M. E., & Tortella, B. J. (2015) · Journal of Blood Medicine · doi:10.2147/jbm.s42669 · Cited by 57
“This process of “primary prophylaxis” was rapidly adopted for younger patients with remarkable reductions in secondary arthropathy due to hemarthrosis.(6) Specialized hemophilia treatment centers came into existence, further enhancing and standardizing the care of hemophilia and providing routine access to orthopedic…”
Emicizumab: the hemophilia A game-changer
Alcedo, P. E., Manucci, P. M., & Kessler, C. M. (2023) · Haematologica · doi:10.3324/haematol.2022.282099 · Cited by 65
Valentino, L. A. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.01980.x · Cited by 45
Self-citationVenous access in haemophilic children: choice and management
Santagostino, E., & Mancuso, M. E. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2009.02156.x · Cited by 45
Hemophilia: New Protein Therapeutics
Pipe, S. W. (2010) · Hematology · doi:10.1182/asheducation-2010.1.203 · Cited by 46
Mulvany, R. D., Zucker-Levin, A. R., Jeng, M., Joyce, C., Tuller, J. M., Rose, J. M., & Dugdale, M. (2010) · Physical Therapy · doi:10.2522/ptj.20080202 · Cited by 45
Wyrwich, K. W., Krishnan, S., Auguste, P., Poon, J. L., von Maltzahn, R., Yu, R., Pierce, G. F., Mei, B., Mahlangu, J. N., & Mackensen, S. V. (2016) · Haemophilia · doi:10.1111/hae.12987 · Cited by 45
Assessment of Treatment Practice Patterns for Severe Hemophilia A: A Global Nurse Perspective
Khair, K., Kingsley, L., Butler, R. B., O'Shea, E., & Christie, B. A. (2008) · Acta Haematologica · doi:10.1159/000121828 · Cited by 45
Management of haemophilic arthropathy
Bossard, D. S., Carrillon, Y., Stieltjes, N., Larbre, J.-P., Laurian, Y., Molina, V., & Dirat, G. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01734.x · Cited by 45
Oldenburg, J., Kulkarni, R., Srivastava, A., Mahlangu, J. N., Blanchette, V. S., Tsao, E., Winding, B., Dumont, J., & Jain, N. (2017) · Haemophilia · doi:10.1111/hae.13353 · Cited by 50
Increased bone resorption in hemophilia
Rodriguez-Merchan, E. C., & Valentino, L. A. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.05.002 · Cited by 46
Self-citationGooding, R., Thachil, J. V., Alamelu, J., Motwani, J., & Chowdary, P. (2021) · Journal of Blood Medicine · doi:10.2147/jbm.s304597 · Cited by 44
UIJL, I. E. M. D., Schepper, A. M. A. D., Camerlinck, M., Grobbee, D. E., & Fischer, K. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02513.x · Cited by 44
Optimizing outcomes for patients with severe haemophilia A
Pipe, S. W., & Valentino, L. A. (2007) · Haemophilia · doi:10.1111/j.1365-2516.2007.01552.x · Cited by 44
Self-citationRagni, M. V., Fogarty, P., Josephson, N. C., Neff, A. T., Raffini, L. J., & Kessler, C. M. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02554.x · Cited by 43
Young, G. A., Auerswald, G., Jiménez‐Yuste, V., Lambert, T., Morfini, M., Santagostino, E., & Blanchette, V. S. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.08.305 · Cited by 43
“Evidence suggests that factor replacement therapy aimed at preventing joint bleeds, referred to as primary prophylaxis, is extremely effective and results in prevention of haemophilic arthropathy [1,2].”
BackgroundManual therapy in the treatment of ankle hemophilic arthropathy. A randomized pilot study
Cuesta‐Barriuso, R., Gómez‐Conesa, A., & Pina, J. A. L. (2014) · Physiotherapy Theory and Practice · doi:10.3109/09593985.2014.902148 · Cited by 43
Real‐world resource use and costs of haemophilia A‐related bleeding
Shrestha, A., Eldar‐Lissai, A., Hou, N., Lakdawalla, D. N., & Batt, K. (2017) · Haemophilia · doi:10.1111/hae.13220 · Cited by 43
Imaging of haemophilic arthropathy in growing joints: pitfalls in ultrasound and MRI
Soliman, M., Daruge, P., Dertkigil, S. S. J., Fernandes, E. D. Á., Negrão, J. R., Mitraud, S. D. A. V., Sakuma, E. T. I., Fernandes, A. R., Zhang, N., Huo, A., et al. (2017) · Haemophilia · doi:10.1111/hae.13249 · Cited by 43
Chen, C. X., Baker, J., & Nichol, M. B. (2017) · Value in Health · doi:10.1016/j.jval.2017.04.017 · Cited by 43
Khair, K., Mazzucconi, M. G., Parra, R., Santagostino, E., Tsakiris, D. A., Hermans, C. R. J. R., Oldenburg, J., Spotts, G. E., Steinitz‐Trost, K. N., & Gringeri, A. (2017) · Haemophilia · doi:10.1111/hae.13361 · Cited by 43
Ogiwara, K., Nogami, K., Matsumoto, N., Noguchi‐Sasaki, M., Hirata, M., Soeda, T., & Shima, M. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02959-x · Cited by 49
Inherited Abnormalities of Coagulation
Kumar, R., & Carcao, M. D. (2013) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2013.09.002 · Cited by 45
Ankle fusion in patients with haemophilia
Bluth, B. E., Fong, Y.-J., Houman, J., Silva, M., & Luck, J. V. (2013) · Haemophilia · doi:10.1111/hae.12114 · Cited by 42
Physical Functioning in Boys with Hemophilia in the U.S.
Monahan, P. E., Baker, J., Riske, B., & Soucie, J. M. (2011) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.09.017 · Cited by 45
Self-citationCurrent Options and New Developments in the Treatment of Haemophilia
Wong, T. E., & Recht, M. (2011) · Drugs · doi:10.2165/11585340-000000000-00000 · Cited by 42
Self-citationCost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
Colombo, G. (2011) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s16670 · Cited by 42
Fernandes, R. M., van der Lee, J. H., & Offringa, M. (2009) · BMC Pediatrics · doi:10.1186/1471-2431-9-77 · Cited by 41
“Number of Participants Median [IQR]# 136 [50-400] 601 [215-2360]”
Peyvandi, F., Berger, K., Seitz, R., Hilger, A., Hecquet, M., Wierer, M., Buchheit, K., O’Mahony, B., Bok, A., Makris, M., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.242735 · Cited by 46
Druzgal, C. H., Kızılocak, H., Brown, J., Sennett, M., & Young, G. A. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14957 · Cited by 42
Nacca, C. R., Harris, A. P., & Tuttle, J. R. (2017) · Orthopedics · doi:10.3928/01477447-20170619-05 · Cited by 42
Collins, P. W., Obaji, S. G., Roberts, H., Gorsani, D., & Rayment, R. (2021) · Haemophilia · doi:10.1111/hae.14201 · Cited by 43
Towards achieving a haemophilia‐free mind
Hermans, C. R. J. R., & Pierce, G. F. (2023) · Haemophilia · doi:10.1111/hae.14807 · Cited by 41
Berntorp, E. E., Astermark, J., Baghaei, F., Bergqvist, D., Holmström, M., Ljungberg, B., Norlund, A., Palmblad, J. E. W., Petrini, P., Stigendal, L., et al. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02723.x · Cited by 42
Outcome measures in haemophilia: a systematic review
Boehlen, F., Graf, L., & Berntorp, E. E. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12369 · Cited by 43
Haemophilia Joint Health Score in healthy adults playing sports
Sluiter, D., Foppen, W., de Kleijn, P., & Fischer, K. (2013) · Haemophilia · doi:10.1111/hae.12290 · Cited by 41
Functional characteristics of N8, a new recombinant FVIII
Christiansen, M. L. S., Balling, K. W., Persson, E., Hilden, I., BAGGER‐SØRENSEN, A., Sørensen, B., Viuff, D., Segel, S., Klausen, N. K., Ezban, M., et al. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02333.x · Cited by 41
Inflammation is key to hemophilic arthropathy
Srivastava, A. (2015) · Blood · doi:10.1182/blood-2015-09-665091 · Cited by 42
Orthopedic disorders of the knee in hemophilia: A current concept review
Rodriguez-Merchan, E. C., & Valentino, L. A. (2016) · World Journal of Orthopedics · doi:10.5312/wjo.v7.i6.370 · Cited by 41
Self-citationRecht, M., Konkle, B. A., Jackson, S. C., Neufeld, E. J., Rockwood, K. J., & Pipe, S. W. (2016) · Haemophilia · doi:10.1111/hae.13066 · Cited by 44
Self-citationHow I manage patients with inherited haemophilia A and B and factor inhibitors
Ljung, R. C. R. (2017) · British Journal of Haematology · doi:10.1111/bjh.15053 · Cited by 41
“…that may trigger the arthropathic process in those subjects, although this is difficult to define on an individual basis, who are more susceptible to developing early changes in the synovia, cartilage and bone after a joint bleed (Lundin et al, 2005; Manco-Johnson et al, 2007; Valentino, 2010).”
BackgroundOutcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate)
Manco‐Johnson, M. J., Warren, B. B., Buckner, T. W., Funk, S. M., & Wang, M. (2021) · Haemophilia · doi:10.1111/hae.14099 · Cited by 44
“Joint physical examination score (max score 90) 1 (0-2) 3 (1-5) 5 (2-8)”
Self-citationConsequences of intra‐articular bleeding in haemophilia: science to clinical practice and beyond
Forsyth, A. L., Rivard, G., Valentino, L. A., Zourikian, N., Hoffman, M., Monahan, P. E., van Meegeren, M. E., & Forriol, F. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02835.x · Cited by 47
Self-citationPrimary prophylaxis in children with haemophilia.
Coppola, A., Capua, M. D., & Simone, C. D. (2008) · PubMed Central · doi:10.2450/2008.0030-08 · Cited by 41
Mancuso, M. E., Croteau, S. E., & Klamroth, R. (2024) · Haemophilia · doi:10.1111/hae.14976 · Cited by 40
“31 To achieve complete protection from all hemophilia-relatedbleedsFVIII/FIXlevelsshouldbeideallykeptinthe normal range however this is still hard to achieve.”
BackgroundTherapeutic Effects of Hepatocyte Transplantation on Hemophilia B
Tatsumi, K., Ohashi, K., Shima, M., Nakajima, Y., Okano, T., & Yoshioka, A. (2008) · Transplantation · doi:10.1097/tp.0b013e31817b9160 · Cited by 41
“The only treatments that are currently available are the replacement therapy with FIX concentrates from plasma-derived or recombinant protein sources (2).”
BackgroundFischer, K., Pouw, M. E., Lewandowski, D., Janssen, M. P., van den Berg, H. M., & van Hout, B. A. (2011) · Haematologica · doi:10.3324/haematol.2010.029868 · Cited by 40
“Cumulative joint bleeds 352 (8-1322) 84 (6-280) 116 (8-400) 85 (8-280)”
InfluentialMolecular approaches for improved clotting factors for hemophilia
Kaufman, R. J., & Powell, J. S. (2013) · Blood · doi:10.1182/blood-2013-07-498261 · Cited by 40
Oldenburg, J., Lacroix‐Desmazes, S., & Lillicrap, D. (2015) · Haematologica · doi:10.3324/haematol.2014.112821 · Cited by 43
“starting before the age of two years, has become the standard of care in severe hemophilia A.(1,2,4)”
BackgroundSoucie, J. M., Grosse, S. D., Siddiqi, A., Byams, V. R., Thierry, J. M., Zack, M. M., Shapiro, A. D., & Duncan, N. (2017) · Haemophilia · doi:10.1111/hae.13275 · Cited by 40
“20 Comparisons of our findings on inhibitors and preference-based HRQoL with those of previous studies are complicated by differences in study design.”
Self-citationIndividualized PK‐based prophylaxis in severe haemophilia
Dargaud, Y. G., Delavenne, X., Hart, D. P., Meunier, S., & Mismetti, P. (2018) · Haemophilia · doi:10.1111/hae.13397 · Cited by 42
Shah, A., Coyle, T., Lalezari, S., Fischer, K., Kohlstaedde, B., Delesen, H., Radke, S., & Michaels, L. A. (2018) · Haemophilia · doi:10.1111/hae.13561 · Cited by 40
Retout, S., Schmitt, C., Petry, C., Mercier, F., & Frey, N. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00904-z · Cited by 40
Abbattista, M., Ciavarella, A., Noone, D., & Peyvandi, F. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.01.010 · Cited by 40
A marker-free system for the analysis of movement disabilities.
Morfini, M., Coppola, A., Franchini, M., & Minno, G. D. (1998) · Europe PMC (PubMed Central) · doi:10.2450/2013.010s · Cited by 43
Pharmacokinetic properties of BAY 81‐8973, a full‐length recombinant factor VIII
Shah, A., Delesen, H., Garger, S. J., & Lalezari, S. (2015) · Haemophilia · doi:10.1111/hae.12691 · Cited by 39
Innovative Pharmacological Therapies for the Hemophilias Not Based on Deficient Factor Replacement
Mannucci, P. M., Mancuso, M. E., Santagostino, E., & Franchini, M. (2016) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1571310 · Cited by 39
Adherence to prophylactic treatment in patients with haemophilia in Germany
Miesbach, W., & Kalnins, W. (2016) · Haemophilia · doi:10.1111/hae.13003 · Cited by 39
Extended Half-Life (EHL) Coagulation Factors: A New Era in the Management of Haemophilia Patients
Ar, M. C., Balkan, C., & Kavaklı, K. (2019) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2019.2018.0393 · Cited by 39
“Regular prophylactic factor replacement to maintain circulating factor levels of >1 IU/dL (1%) has been recommended as the optimal therapy for people with severe hemophilia, based on evidence showing that prophylaxis is associated with substantial reduction in bleeding episodes and related complications and consequent…”
BackgroundUncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns
Pierce, G. F. (2020) · Haemophilia · doi:10.1111/hae.14023 · Cited by 39
Stephensen, D., Drechsler, W. I., Winter, M. R., & Scott, O. M. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01934.x · Cited by 39
Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease
Metjian, A. D., WANG, C., Sood, S. L., Cuker, A. C., PETERSON, S. M., Soucie, J. M., Konkle, B. A., & THE HTCN STUDY INVESTIGATORS (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02025.x · Cited by 39
Self-citationThe bleeding phenotype in people with nonsevere hemophilia
Kloosterman, F. R., Zwagemaker, A., Bagot, C. N., Beckers, E. A. M., Castaman, G., Cnossen, M. H., Collins, P. W., Hay, C. R. M., Hof, M. H. P., Gorkom, B. A. P. L., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007620 · Cited by 40
“Subcutaneous 345 (23) 155 (20) 190 (25) 114 (24) 53 (25) 23 (33)”
Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review
Malec, L. M., & Matino, D. (2023) · Haemophilia · doi:10.1111/hae.14866 · Cited by 42
“11,12 However, the Joint Outcomes Study—Continuation showed that early prophylaxis ( 2.5 years of age) is insufficient to prevent all joint damage, with only 2 of 14 participants (14”
BackgroundInfluentialExtending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin
Pipe, S. W., Weimer, T., Schulte, S., & Metzner, H. J. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-03-0213 · Cited by 39
“Regular, long-term prophylaxis with factor concentrates prevents recurrent haemorrhagic episodes and the resulting development of haemophilic arthropathy, with associated improvement in clinical outcomes, quality of life and life expectancy in patients with haemophilia (2, 3).”
BackgroundLock, J., Raat, H., Duncan, N., Shapiro, A. D., Beijlevelt, M., Peters, M., Tamminga, R. Y. J., Leebeek, F. W. G., Moll, H. A., & Cnossen, M. H. (2014) · Haemophilia · doi:10.1111/hae.12463 · Cited by 43
Self-citationKashiwakura, Y., Mimuro, J., Ōnishi, A., Iwamoto, M., Madoiwa, S., Fuchimoto, D., Suzuki, S., Suzuki, M., Sembon, S., Ishiwata, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049450 · Cited by 43
“Prophylactic administration of FVIII is effective in preventing harmful bleeding; however, hemophilia A patients are still not free from the risks of life-threatening intracranial and other harmful bleeding [1] [2].”
BackgroundLövgren, K. M., Søndergaard, H., Skov, S., & Wiinberg, B. (2016) · Haemophilia · doi:10.1111/hae.13075 · Cited by 41
Aspects of prophylactic treatment of hemophilia
Ljung, R. C. R. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0103-3 · Cited by 38
“The existence of subclinical bleeds was suggested several years ago from Sweden [18, 19], and has been suggested as cause of advanced joint changes found on MRI in patients reporting no or very few joint bleeds [5, 20].”
BackgroundMeasurement properties of the Haem‐A‐QoL in haemophilia clinical trials
Mackensen, S. V., Eldar‐Lissai, A., Auguste, P., Krishnan, S., von Maltzahn, R., Yu, R., & Wyrwich, K. W. (2016) · Haemophilia · doi:10.1111/hae.13140 · Cited by 38
Zhang, Y., Roberts, J., Tortorici, M. A., Veldman, A., Ledger, K. S., Feussner, A., & Sidhu, J. S. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13662 · Cited by 38
Feldman, B. M., Rivard, G., Babyn, P., Wu, J. K., Steele, M., Poon, M., Card, R., Israels, S. J., Laferriere, N., Gill, K., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30048-6 · Cited by 38
Cuesta‐Barriuso, R., Gómez‐Conesa, A., & Pina, J. A. L. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0884-5 · Cited by 39
Oldenburg, J., Yan, S., Maro, G. S., Krishnarajah, G., & Tiede, A. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1662675 · Cited by 38
Ucero‐Lozano, R., Pina, J. A. L., Ortiz‐Pérez, A., & Cuesta‐Barriuso, R. (2021) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-021-04319-0 · Cited by 46
“Prophylactic treatment has been shown to be effective for reducing bleeding and its consequences [3], but because of its cost and associated discomfort, not all patients choose it [4].”
BackgroundKey issues in inhibitor management in patients with haemophilia.
Gomez, K., Klamroth, R., Mahlangu, J. N., Mancuso, M. E., Mingot‐Castellano, M. E., & Ozelo, M. C. (2014) · Europe PMC (PubMed Central) · doi:10.2450/2013.0246-12 · Cited by 39
Metadata
- Authors
- Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., Valentino, L. A., Hoots, W. K., Buchanan, G. R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G. A., Thompson, A. A., McRedmond, K., Soucie, J. M., Austin, H., & Evatt, B. L.
- Affiliations
- University of Colorado Denver (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-08-09
- Volume
- 357
- Issue
- 6
- Pages
- 535-544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2167801052
- Cited by
- 1,950
- References
- 27
- Citations by year
- 2026: 57 · 2025: 70 · 2024: 98 · 2023: 115 · 2022: 106 · 2021: 123 · 2020: 127 · 2019: 110 · 2018: 114 · 2017: 107 · 2016: 123 · 2015: 116 · 2014: 131 · 2013: 116 · 2012: 112
- FWCI
- 45.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (U27/CCU812106, R00069)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hemophilia A, severe hemophilia, prophylaxis, episodic treatment, recombinant factor VIII, joint destruction, factor VIII inhibitors, joint hemorrhage, children, central venous catheter complications
- MeSH terms
- Child, Child, Preschool, Drug Administration Schedule, Factor VIII, Follow-Up Studies, Hemarthrosis, Hemophilia A, Hemorrhage, Humans, Infant, Infusions, Intravenous, Joint Diseases, Male, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.